Trial
NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Non-hodgkin's Lymphoma
Intervention
IMMU-114
Why stopped
Study was stopped due to insufficient efficacy and very slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-19